Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2023 | Targeting CGRP: Is it better to target the ligand or receptor in migraine prevention?

Claudia Altamura, MD, PhD, Campus Bio-Medico, University of Rome, Rome, Italy, provides a comprehensive overview of recent developments in therapies targeting the CGRP receptor or ligand for the treatment of migraine. Although both drug types act on the CGRP pathway, there is new evidence suggesting that CGRP receptor antagonists also show affinity with amylin, which the drugs targeting the CGRP ligand don’t. When choosing between the two treatment options, it is important to consider the complete clinical profile of patients, including comorbidities and preferences. Both drug types have established effectiveness but may have different side effects. Dr Altamura recognizes the complementary nature of these approaches, presenting healthcare professionals with more opportunities to tailor treatments to individual patients. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Claudia Altamura has received personal fees from Teva, Lundbeck, Eli Lilly, and Novartis.